AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29901926 — intervention group
Group type: COMPARATOR
Intervention: Front-cutting instruments
Number of subjects: 60
Study 29901926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both instruments
Number of subjects: 60
Study 25041619 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic living cell bioformulation with compression therapy
Number of subjects: 227
Study 25041619 — intervention group
Group type: COMPARATOR
Intervention: Standard care with compression therapy
Number of subjects: 227
Study 22943926 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose delivery system (SDS)
Number of subjects: 48
Study 22943926 — intervention group
Group type: COMPARATOR
Intervention: Multi-dose delivery system (MDS)
Number of subjects: 48
Study 22943926 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose delivery system (SDS) and Multi-dose delivery system (MDS)
Number of subjects: 48
Study 20934572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg + Atorvastatin 40 mg + Ezetimibe 10 mg (FA + Atorva/Eze)
Number of subjects: 543
Study 20934572 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg + Ezetimibe 10 mg (Atorva/Eze)
Number of subjects: 543
Study 18171584 — intervention group
Group type: EXPERIMENTAL
Intervention: One-site phacotrabeculectomy
Number of subjects: 80
Study 18171584 — intervention group
Group type: COMPARATOR
Intervention: Two-site phacotrabeculectomy
Number of subjects: 80
Study 17002609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response during the first days of treatment
Number of subjects: 260
Study 17002609 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered mental state
Number of subjects: 260
Study 17002609 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial PaH <7.35 mm Hg
Number of subjects: 260
Study 17002609 — intervention group
Group type: EXPERIMENTAL
Intervention: PaO2 <60 mm Hg
Number of subjects: 260
Study 17002609 — intervention group
Group type: EXPERIMENTAL
Intervention: History of heart failure
Number of subjects: 260
Study 17002609 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who failed to respond
Number of subjects: 260
Study 14643272 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 10955871 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE with lenograstim support (150 microg/m2/day subcutaneously, days 4-13)
Number of subjects: 280
Study 10955871 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE with lenograstim support
Number of subjects: 280
Study 10955871 — intervention group
Group type: COMPARATOR
Intervention: ACE alone
Number of subjects: 280
Study 8834690 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental biphasic waveform (LVLD) with a single 450-microF capacitor and 60% tilt
Number of subjects: 25
Study 8834690 — intervention group
Group type: COMPARATOR
Intervention: Standard biphasic waveform (STD) with two 250-microF capacitors in series and 80% tilt
Number of subjects: 25
Study 8834690 — intervention group
Group type: EXPERIMENTAL
Intervention: Both waveforms (STD and LVLD)
Number of subjects: 25
Study 1427379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 18
Study 1427379 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (100 mg)
Number of subjects: 18
Study 1427379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3900796 — intervention group
Group type: EXPERIMENTAL
Intervention: Milenperone (2 X 10 mg daily for 6 weeks)
Number of subjects: 21
Study 3900796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3900796 — intervention group
Group type: COMPARATOR
Intervention: Milenperone or Placebo
Number of subjects: 21
Study 30891608 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD recipients aged ≥80 years
Number of subjects: 300
Study 30891608 — intervention group
Group type: COMPARATOR
Intervention: Controls aged <80 years
Number of subjects: 300
Study 30891608 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly group
Number of subjects: 300
Study 29566987 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial collagen nerve conduit
Number of subjects: 49
Study 29566987 — intervention group
Group type: COMPARATOR
Intervention: Autologous nerve graft
Number of subjects: 49
Study 27823996 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinming8631 DR
Number of subjects: 225
Study 27823996 — intervention group
Group type: COMPARATOR
Intervention: Talos DR
Number of subjects: 225
Study 25299041 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseation
Number of subjects: 692
Study 25299041 — intervention group
Group type: EXPERIMENTAL
Intervention: Confluent granulomas
Number of subjects: 692
Study 25299041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcers lined by epithelioid histiocytes
Number of subjects: 692
Study 23106881 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nephroureterectomy (clipping the distal ureter prior to NU)
Number of subjects: 85
Study 23106881 — intervention group
Group type: COMPARATOR
Intervention: Standard nephroureterectomy (traditional standard NU)
Number of subjects: 85
Study 20673500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track surgery (FTS)
Number of subjects: 80
Study 20673500 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (Control)
Number of subjects: 80
Study 19029267 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 44
Study 19029267 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 44
Study 19029267 — intervention group
Group type: COMPARATOR
Intervention: Comparison between on-pump and off-pump CABG
Number of subjects: 44
Study 15918827 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular occlusion of the aneurysm using detachable coils
Number of subjects: 34
Study 15918827 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy and clipping of the aneurysm
Number of subjects: 34
Study 15918827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri‐operative care for patients undergoing interventional neuroradiology procedures
Number of subjects: 34
Study 12884417 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE intervention program
Number of subjects: 49
Study 12884417 — intervention group
Group type: COMPARATOR
Intervention: Comparison program
Number of subjects: 49
Study 10727924 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium-YAG laser stimulation (540 mJ pulses)
Number of subjects: 23
Study 8772689 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine (PNE) levels above the median of 393 pg/mL
Number of subjects: 514
Study 1471822 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 101
Study 1471822 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 101
Study 6419264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cyano-imipramine (1 mg rising to 3 mg daily for 7 days)
Number of subjects: 0
Study 6419264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29107059 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMEX (neuromuscular exercise)
Number of subjects: 93
Study 29107059 — intervention group
Group type: COMPARATOR
Intervention: PHARMA (optimized pharmacological treatment)
Number of subjects: 93
Study 23283758 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a dosage of .3 mg/kg
Number of subjects: 63
Study 23283758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 25823758 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed instructions regarding the infant's environment, positioning, and handling
Number of subjects: 0
Study 25823758 — intervention group
Group type: COMPARATOR
Intervention: Standard positioning instructions to prevent SIDS
Number of subjects: 0
Study 23506414 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope (BF)
Number of subjects: 100
Study 23506414 — intervention group
Group type: COMPARATOR
Intervention: GlideScope (GS)
Number of subjects: 100
Study 23506414 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 100
Study 21962090 — intervention group
Group type: EXPERIMENTAL
Intervention: FAN educational program
Number of subjects: 275
Study 21962090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study 18376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory mode for steering task
Number of subjects: 0
Study 18376536 — intervention group
Group type: COMPARATOR
Intervention: Visual mode for steering task
Number of subjects: 0
Study 18376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory mode for monitoring task
Number of subjects: 0
Study 18376536 — intervention group
Group type: COMPARATOR
Intervention: Visual mode for monitoring task
Number of subjects: 0
Study 16490069 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional roles of health teams in elementary schools (providing first aid, ensuring school hygiene)
Number of subjects: 35
Study 16490069 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of students with behavioral problems, Evaluation of students with low academic performance, Follow up and care of students with behavioral problems and low performance
Number of subjects: 35
Study 16490069 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-based model of health services in schools
Number of subjects: 35
Study 12806341 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etching before bonding metallic premolar brackets (Group A)
Number of subjects: 60
Study 12806341 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide bleaching agent, bonded immediately (Group B)
Number of subjects: 60
Study 12806341 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide bleaching agent, stored in artificial saliva for 30 days before bonding (Group C)
Number of subjects: 60
Study 10827367 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE‐guided subcutaneous enoxaparin bridge therapy
Number of subjects: 200
Study 10827367 — intervention group
Group type: COMPARATOR
Intervention: TEE‐guided intravenous unfractionated heparin bridge therapy
Number of subjects: 200
Study 10827367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 8648019 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 8
Study 8648019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1513578 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface modified IOL
Number of subjects: 524
Study 1513578 — intervention group
Group type: COMPARATOR
Intervention: Conventional PMMA IOL
Number of subjects: 524
Study 6526768 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement with varying pay amounts ($0, $1.50, $3, $6, $12 per day) for reduced afternoon CO levels
Number of subjects: 23
Study 6526768 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement with varying pay amounts
Number of subjects: 23
Study 29276837 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) in lung cancer patients (4 sessions)
Number of subjects: 258
Study 29276837 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) in breast cancer patients (6 sessions)
Number of subjects: 258
Study 29276837 — intervention group
Group type: COMPARATOR
Intervention: Control group for lung cancer patients (4 sessions)
Number of subjects: 258
Study 29276837 — intervention group
Group type: COMPARATOR
Intervention: Control group for breast cancer patients (6 sessions)
Number of subjects: 258
Study 28666310 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support (SMS)
Number of subjects: 90
Study 28666310 — intervention group
Group type: COMPARATOR
Intervention: Common intervention (CI)
Number of subjects: 90
Study 26531095 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation (1800 mg per day)
Number of subjects: 20
Study 25294055 — intervention group
Group type: EXPERIMENTAL
Intervention: SaiLuoTong 360 mg per day for 52 weeks
Number of subjects: 372
Study 25294055 — intervention group
Group type: EXPERIMENTAL
Intervention: SaiLuoTong 240 mg per day for 52 weeks
Number of subjects: 372
Study 25294055 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the double-blind phase
Number of subjects: 372
Study 25294055 — intervention group
Group type: EXPERIMENTAL
Intervention: SaiLuoTong 360 mg per day during the extension phase
Number of subjects: 372
Study 25294055 — intervention group
Group type: EXPERIMENTAL
Intervention: SaiLuoTong 240 mg per day during the extension phase
Number of subjects: 372
Study 22459341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 90
Study 22459341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 90
Study 22459341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19653976 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (7.5 g daily for 12 weeks)
Number of subjects: 33
Study 19653976 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (7.5 g daily for 12 weeks)
Number of subjects: 33
Study 19653976 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (7.5 g daily during open-label phase)
Number of subjects: 33
Study 19653976 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (7.5 g daily during open-label phase)
Number of subjects: 33
Study 17761977 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 50 mg daily for 21 consecutive days
Number of subjects: 166
Study 17761977 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 150 mg daily for 21 consecutive days
Number of subjects: 166
Study 17761977 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 450 mg daily for 14 consecutive days followed by 7 days of no treatment
Number of subjects: 166
Study 15549466 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine, 12 ml
Number of subjects: 18
Study 15549466 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine, 18 ml
Number of subjects: 18
Study 11593302 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 0
Study 11593302 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine supplementation
Number of subjects: 0
Study 11593302 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation
Number of subjects: 0
Study 11593302 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented diet
Number of subjects: 0
Study 9504845 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to faces in right occipito-temporal channels at a latency of 140 ms
Number of subjects: 14
Study 9504845 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-specific response
Number of subjects: 14
Study 9504845 — intervention group
Group type: EXPERIMENTAL
Intervention: Source modelling
Number of subjects: 14
Study 9504845 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of image types
Number of subjects: 14
Study 8836468 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (used alone)
Number of subjects: 0
Study 8836468 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (in combination with other drugs)
Number of subjects: 0
Study 8836468 — intervention group
Group type: EXPERIMENTAL
Intervention: Other medications containing yohimbine
Number of subjects: 0
Study 8836468 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (uncontrolled trials)
Number of subjects: 0
Study 8836468 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine plus other drugs (uncontrolled trials)
Number of subjects: 0
Study 2271802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavioral medicine interventions (two types)
Number of subjects: 80
Study 2271802 — intervention group
Group type: COMPARATOR
Intervention: Information group focusing on stress management
Number of subjects: 80
Study 492047 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml Trental (= 200 mg pentoxifylline)
Number of subjects: 33
Study 492047 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (= placebo)
Number of subjects: 33
Study 492047 — intervention group
Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 33
Study 30865232 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1169
Study 30865232 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1169
Study 30865232 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 1169
Study 27054321 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea supplementation (0.56 g/d epigallocatechin-gallate + 0.28 ∼ 0.45 g/d caffeine)
Number of subjects: 58
Study 27054321 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 58
Study 27054321 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea supplementation
Number of subjects: 58
Study 24236646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy (LFD)
Number of subjects: 35
Study 24236646 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control foods (CON)
Number of subjects: 35
Study 21802739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 38
Study 21802739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 38
Study 19336626 — intervention group
Group type: COMPARATOR
Intervention: Coca‐Cola
Number of subjects: 90
Study 19336626 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosehip fruit tea
Number of subjects: 90
Study 19336626 — intervention group
Group type: EXPERIMENTAL
Intervention: Black herbal tea
Number of subjects: 90
Study 19336626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint‐mate herbal tea
Number of subjects: 90
Study 19336626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint‐lemon herbal tea
Number of subjects: 90
Study 19336626 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 90
Study 16689181 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536 yoghurt (yoghurt containing Bifidobacterium longum BB536)
Number of subjects: 40
Study 16689181 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536 yoghurt
Number of subjects: 40
Study 16689181 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 40
Study 15298638 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (100 IE/kg)
Number of subjects: 22
Study 15298638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11777230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with heel pain (BMI 30.4 +/- 0.7)
Number of subjects: 0
Study 11777230 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMI 28.2 +/- 0.7)
Number of subjects: 0
Study 11777230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with heel pain
Number of subjects: 0
Study 9170121 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 12
Study 9170121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9170121 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 12
Study 1555981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- or postoperative radiation therapy (45 Gy/5 weeks)
Number of subjects: 960
Study 1555981 — intervention group
Group type: COMPARATOR
Intervention: Tangential 60Co fields for left-sided tumors
Number of subjects: 960
Study 1555981 — intervention group
Group type: COMPARATOR
Intervention: Less radiation to the myocardium (electrons or right-sided tumors)
Number of subjects: 960
Study 2582386 — intervention group
Group type: EXPERIMENTAL
Intervention: RS4 mode
Number of subjects: 18
Study 2582386 — intervention group
Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 18
Study 2582386 — intervention group
Group type: EXPERIMENTAL
Intervention: RS4 function
Number of subjects: 18
Study 31215468 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic care program combining DMP with spiritual needs assessment and social contact/self-care exploration.
Number of subjects: 0
Study 31215468 — intervention group
Group type: COMPARATOR
Intervention: Standard disease management program (DMP) as usual.
Number of subjects: 0
Study 29068050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose blowing at least twice daily for the first 7 postoperative days
Number of subjects: 40
Study 29068050 — intervention group
Group type: COMPARATOR
Intervention: Refraining from nose blowing
Number of subjects: 40
Study 26980614 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS administered over ipsilesional primary motor cortex (M1-stimulation group)
Number of subjects: 26
Study 26980614 — intervention group
Group type: COMPARATOR
Intervention: Control-stimulation group (parieto-occipital vertex)
Number of subjects: 26
Study 25325205 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day bupropion
Number of subjects: 42
Study 25325205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22301476 — intervention group
Group type: EXPERIMENTAL
Intervention: CCIV (cell-culture-derived influenza vaccine)
Number of subjects: 3604
Study 22301476 — intervention group
Group type: COMPARATOR
Intervention: TIV (conventional egg-derived trivalent influenza vaccine)
Number of subjects: 3604
Study 22301476 — intervention group
Group type: EXPERIMENTAL
Intervention: CCIV
Number of subjects: 3604
Study 22301476 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 3604
Study 20406241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg (up-titrated to 300 mg)
Number of subjects: 175
Study 20406241 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg (up-titrated to 10 mg)
Number of subjects: 175
Study 17623606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular analgesic mixture (adrenaline, morphine, bupivacaine) administered during ACL reconstruction (groups 3 and 4)
Number of subjects: 85
Study 17623606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular analgesic mixture (adrenaline, morphine, bupivacaine)
Number of subjects: 85
Study 17623606 — intervention group
Group type: COMPARATOR
Intervention: No intra-articular analgesic (groups 1, 2, and 5)
Number of subjects: 85
Study 16094780 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) in Group 1 (Spastic quadriparesis patients with impaired consciousness)
Number of subjects: 21